Moderna Agrees $950M Patent Settlement, Focuses on Infectious Disease Pipeline
Moderna agreed to pay $950 million to settle global patent litigation with Arbutus Biopharma and Genevant Sciences over its Spikevax and mRESVIA vaccines while reserving the right to appeal for immunity. The deal clears the way for Moderna to redirect R&D resources toward its infectious disease pipeline.
1. Patent Litigation Settlement
Moderna agreed to pay $950 million to Arbutus Biopharma and Genevant Sciences to resolve global patent claims over its Spikevax and mRESVIA vaccines while preserving the right to appeal for immunity from ongoing royalties.
2. Strategic Focus Post-Settlement
The settlement removes legal uncertainties and allows Moderna to reallocate resources toward its infectious disease pipeline, including next-generation vaccine candidates and emerging pathogen therapies, as CEO Stéphane Bancel highlighted that reduced legal distractions will accelerate development.